US › Healthcare

Veracyte Inc (VCYT)

US · Healthcare · Diagnostics & Research

$46.41+3.48%

Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue

$150.3M

Revenue YoY

+15.5%

Net profit

$25.5M

Profit YoY

+2701.0%

EPS

$0.37

EPS estimate

$0.29

Net margin

17.0%

EPS came in at 0.37 against a street estimate of 0.29 — a beat of 27.6%.

Key statistics

Market cap

$3.70B

P/E

33.1

Forward P/E

26.9

P/B

2.65

Book value

$16.50

EPS (TTM)

$1.40

52-week high

$60.91

52-week low

$23.35

50-day MA

$53.31

200-day MA

$41.89

Beta

1.93

Analyst view

Analysts rate Veracyte Inc a buy (9 buy, 1 hold, 1 sell out of 11) with an average price target of $58.60.

Shareholding

Insiders

0.54%

Institutions

113.46%

Largest institutional holders

Fund	Stake
BlackRock Inc	16.51%
FMR Inc	9.73%
Artisan Partners Limited Partnership	6.89%
State Street Corp	6.32%
Vanguard Portfolio Management, LLC	5.57%
Vanguard Capital Management, LLC	4.43%
ARK Investment Management LLC	3.83%
Dimensional Fund Advisors, Inc.	3.61%

Recent filings & reports

Document	Date
Quarterly report · Q2 2026	2026-07-31
Results announced · Q3 2026	2026-07-30
Board / officer change · Q2 2026	2026-06-11
Quarterly report · Q1 2026	2026-05-06
Results announced · Q2 2026	2026-05-05
Proxy statement · Q2 2026	2026-04-22
Board / officer change · Q1 2026	2026-03-16
Annual report FY2025	2026-02-26

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Veracyte Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.